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ABSTRACT - PURPOSE: Our working hypothesis is that bioactive phytochemicals that are important
constituents of Traditional Chinese Medicine and their defined mixtures have potential as complementary therapy
for chemoprotection against adverse drug reactions whose toxicity is not related to the pharmacological action of
the drug but where oxidative and nitrosative stress are causative factors. METHODS: In this investigation we
measured cytotoxicity, lipid peroxidation, protein carbonylation and ROS/NOS-mediated changes in the disulfide
proteome of Jurkat E6.1 cells resulting from exposure to sulfamethoxazole N-hydroxylamine with or without pretreatment with low µM concentrations of baicalein, crocetin, resveratrol and schisanhenol alone and in defined
mixtures to compare the ability of these treatment regimens to protect against ROS/RNS toxicity to Jurkat E6.1
cells in culture. RESULTS: Each of the Traditional Chinese Medicine constituents and defined mixtures tested
had significant chemoprotective effects against the toxicity of ROS/RNS formed by exposure of Jurkat E6.1 cells
to reactive metabolites of sulfamethoxazole implicated as the causative factors in adverse drug reactions to sulfa
drugs used for therapy. At equimolar concentrations, the defined mixtures tended to be more effective
chemoprotectants overall than any of the single constituents against ROS/RNs toxicity in this context.
CONCLUSIONS: At low µM concentrations, defined mixtures of TCM constituents that contain ingredients
with varied structures and multiple mechanisms for chemoprotection have excellent potential for complementary
therapy with sulfa drugs to attenuate adverse effects caused by oxidative/nitrosative stress. Typically, such
mixtures will have a combination of immediate activity due to short in vivo half-lives of some ingredients cleared
rapidly following metabolism by phase 2 conjugation enzymes; and some ingredients with more prolonged halflives and activity reliant on phase 1 oxidation enzymes for their metabolic clearance.
This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For
Readers”) may comment by clicking on ABSTRACT on the issue’s contents page.
_______________________________________________________________________
It is commonly accepted that ADRs can be
divided into two general classes, type A and type B
(3). Type A reactions are dose-dependent and related
to the pharmacological action of the drug, making
them predictable. Type B reactions, on the other
hand, are not predictable from the pharmacological
action of the administered drug, do not show dosedependency and have delayed onset, reasons they are
also called idiosyncratic ADRs.
_________________________________________

INTRODUCTION
Adverse drug reactions (ADRs) are unintended
consequences from drugs administered in
recommended, standard doses for on label conditions
and symptoms that cause increased morbidity, and
even death (1). ADRs are a significant problem that
accompanies administration of many drug classes,
including the sulfonamide, sulfamethoxazole
(SMX). The incidence of SMX-induced ADRs is
reported to be 3-8% of treated patients but this rate
increases dramatically to approximately 50% in
oxidatively stressed patients infected with HIV (2).
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exposure to SMX-NHOH results in the formation of
ROS and intracellular GSH depletion (14,15); SMX
(75 µM) increases ROS production and lipid
peroxidation in BRL3A cells (16); and increasing
SMX concentrations (up to 1.5 mM) result in
concentration-dependent
increases
in
ROS
generation in normal human dermal fibroblasts (17).
This is also supported by reports that ROS are
formed during the oxidative metabolism of many
xenobiotics in vivo (18). There remains controversy
as to whether specific ADRs are due to covalent
modification of proteins by electrophilic metabolites
or due to ROS/RNS causing modifications of
essential macromolecules, including proteins, lipids
and nucleic acids (19,20). In our opinion, either of
these mechanisms can cause a drug-dependent
hypersensitivity reaction but the intensity of the
allergic response is intensified if both occur
concomitantly, as with SMX (Figure 1).
In this context, we hypothesize that purified
bioactive constituents of TCM that are potent
chemoprotectant agents against ROS and NOS in
vivo are candidates for complementary therapy for
ROS- or RNS-mediated ADRs. We also postulate
that defined mixtures of effective phytochemicals
with diverse structures, different mechanisms of
chemoprotectant action and different rates of
metabolic elimination will be more effective than
equimolar amounts of single TCM chemicals for
complementary therapy in vivo.
The TCM phytochemicals evaluated here for
chemoprotection against SMX-NHOH toxicity in
vitro include Baicalein (BE), 5,6,7-trihydroxy-2phenylchromen-4-one (Figure 2A); Crocetin (Cro),
(2E,4E,6E,8E,10E,12E,14E)-2,6,11,15-tetramethylhexadeca-2,4,6,8,10,12,14-heptaenedioic
acid
(Figure 2B); trans-Resveratrol (Res), 5-[(E)-2-(4hydroxyphenyl)ethenyl]benzene-1,3-diol
(Figure
2C); and Schisanhenol (Sal), 5,6,7,8-tetrahydro2,3,10,11,12-pentamethoxy-6,7-dimethyldibenzo(a,c)cycloocten-1-ol (Figure 2D). Although all have
antioxidant activity, the mechanisms for this activity
vary somewhat for each chemical, in concert with
their diverse structures (Figure 2).
BE, a flavonoid derived from the root of
Scutellaria baicalensis is a constituent of multiple
TCM prescriptions. It is used extensively as a
remedy for treatment of respiratory tract infection,
cancer (21) dysentery, jaundice, hepatitis and
hypertension (22).

Type B reactions are less common, accounting for
20-25% of total ADRs (4). Idiosyncratic ADRs can
be either immune-based, frequently termed allergic
or drug hypersensitivity, or not have an
immunological basis, in which case they are called
pseudoallergic or non-allergic hypersensitivity
reactions (5). Sulfonamides cause a variety of drug
hypersensitivity-based
idiosyncratic
ADRs
including fever, lymphadenopathy, skin rashes,
hepatitis, nephritis, and blood dyscrasias, all of
which are attributed to SMX reactive metabolites (6).
Consequently the metabolism of arylamines,
including SMX, and the disposition of parent drug
and its metabolites (Figure 1) become crucial in
understanding the mechanisms responsible for these
ADRs. The major phase 1 metabolic pathway for
SMX is N-acetylation to its N-acetamide although
minor conjugation to an N-glucuronide also occurs
(7). These are both detoxication reactions resulting
in rapid elimination of SMX from the body.
However, smaller and patient-variable amounts (up
to 5%) of SMX are oxidized to sulfamethoxazole Nhydroxylamine (SMX-NHOH), a metabolic
activation reaction, primarily by the P450
monooxygenase isozyme, CYP2C9 (8) but also by
myeloperoxidase (MPO) in activated neutrophils and
lymphocytes (9); this latter reaction is likely more
important in the etiology of the ADRs. SMX-NHOH
undergoes auto-oxidation to the corresponding
sulfamethoxazole N-nitroso metabolite (SMX-NO)
believed responsible for idiosyncratic toxicity of
SMX (10,11), subsequent to formation of drugprotein antigens by covalent reaction with selected
proteins (6,12). Importantly, dendritic cells can
convert SMX to SMX-NO intracellularly and
generate co-stimulatory signals required to initiate a
primary immune response (13).
In the absence of adequate detoxication (for
example, by depletion of intracellular glutathione
(GSH)), the immunogenic SMX-NO preferentially
reacts with (ionized) reactive cysteine thiols of
cellular proteins to form adducts, some of which are
recognized as neo-antigens by the immune system.
These haptens then provide an antigenic signal to T
cells and elicit a T cell-mediated immune response
which presents clinically as delayed-type
hypersensitivity (Figure 1; 10,13). The SMX
metabolites SMX-NHOH and SMX-NO are known
to generate oxidative and nitrosative stress by
forming reactive oxygen species (ROS) and reactive
nitrogen species (RNS) (Figure 1) (10,14-17). This is
consistent with the observations that lymphocyte
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or Sal and of two defined mixtures. The first (MIX
1) contains equimolar concentrations of BE, Cro,
Res and Sal; the second mixture (MIX 2) contains
equimolar concentrations of BE, Cro and Res. High
numbers of T cells in blood and skin from patients
with drug hypersensitivity reactions led researchers
to conclude these cells function via an immune
mechanism to regulate the development of immuneinduced ADRs (34), the reason we selected Jurkat
E6.1 cells for this study.
The toxicological endpoints evaluated include
cytotoxicity (lactate dehydrogenase (LDH) release);
lipid peroxidation (analysis of lipid hydroperoxides
formed) and protein carbonylation (analysis of
protein aldehydes and ketones). In addition, we
performed reductive-two dimensional SDSpolyacrylamide gel electrophoresis (R2D SDSPAGE) on lysate from control and treated Jurkat
E6.1 cells to determine the number of protein mixed
disulfides formed as a result of treatment with SMXNHOH. This disulfide proteome is a measure of the
reversible oxidation of redox-regulated proteins
containing ionized cysteine protein thiol residues to
homodimeric (P-SS-P) or heterodimeric (P-SS-P’)
protein-protein disulfides. Both ROS and RNS carry
out this oxidation.

Cro, one of the major constituents of saffron, is a
carotenoid found in Crocus sativus (23) with
reported anti-cancer and anti-atherosclerotic activity
and effects that attenuate ethanol-induced memory
impairment (24). Res is a trans-stilbene polyphenol
often isolated from the root of white hellebore (25).
It is a common constituent of TCM prescriptions
investigated for chemoprotection against aging,
inflammation (26), cancer, neurodegeneration (27),
diabetes, viral infection and Alzheimer’s (28). Sal is
a dibenzocyclooctene lignin isolated from
Schisandra rubriflora Rhed, an herb common in
TCM prescriptions. Studies with this purified TCM
have been uncommon because of its restricted
availability. Sal effectively targets mitochondria,
inhibiting lipid peroxidation (29), swelling, and
reduction of membrane fluidity due to ROSmediated damage (30). It is also an effective
scavenger of superoxide, R·-, RO·-, and ROO·radicals (31) and is reported to possess anti-tumor,
anti-hepatitis (32), detoxicant, anti-HIV and
attenuation of platelet-activating factor activity (33).
We elected to use Jurkat E6.1cells, a human
leukemic T cell lymphoblast line, to evaluate the
toxicity of the SMX metabolite, SMX-NHOH and
the attenuation of this toxicity by low µM
concentrations of the TCM constituents BE, Cro, Res

A

B

D
C

Figure 2: Three dimensional structures of Baicalein (BE, A); Crocetin (Cro, B); trans-Resveratrol (Res, C); and Schisanhenol
(Sal; D). (From PubChem Public Chemical Database, http://pubchem.nbi.nlm.nih.gov)
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centrifuged at 500×g (Beckman GS-15R centrifuge)
for 10 min. The pellet was washed with 50 ml
phosphate buffered saline (PBS; 1.15×105 cells/ml;
5% Na2HPO4, 0.2% KH2PO4, 8.0% NaCl, 0.2%
KCl, pH7.4) and centrifuged again. For experiments,
cells (5×105 cells/ml) were resuspended in RPMI
1640
medium
supplemented
with
Penicillin/Streptomycin (P/S), and routinely divided
into multiple groups. They were seeded at 1×105
cells/well in triplicate for each group in flat-bottom
96-well plates. All test incubations were in a 5% CO2
humidified environment at 37 ºC and each
experiment was repeated at least 3 times with a
different cell culture each time.
The effects of the TCM constituents (BE, Cro,
Res or Sal) alone and in combination; MIX 1
(equimolar mixture of BE, Cro, Res, Sal) and MIX 2
(equimolar mixture of BE, Cro and Res without Sal)
were determined with Jurkat E6.1 cells in RPMI
medium treated with solvent (no more than 0.2%
DMSO; solvent control), various concentrations (0400 µM) of BE, Cro, Res, Sal, MIX 1 or MIX 2 to
evaluate their cytotoxicity; and at 5 and 20 µM to
evaluate chemoprotection against the toxicity of 400
µM of SMX or its reactive metabolite, SMX-NHOH.
For chemoprotection experiments, cells were
typically incubated with TCM constituents for 30
min before addition of SMX or SMX-NHOH. Cell
protein concentrations were routinely determined
with the Lowry assay (37).

The purpose of this study is to determine whether
or not low µM concentrations of 4 pure TCM
phytochemicals with potent antioxidant activity
alone or in defined mixtures have potential for
complementary therapy with sulfonamides for
chemoprotection against ADRs to these drugs.
MATERIALS AND METHODS
Chemicals and Cell Culture Supplies
The purest TCM constituents commercially
available (>95%) were used throughout; BE was
purchased from Aldrich Chem. Co. (Milwaukee,
WI); Cro from MP Biomedicals, LLC (Solon, Ohio);
and Res from Sigma-Aldrich (Oakville, ON,
Canada). Sal (> 99%) was isolated and purified from
Schisandra rubriflora in the laboratory of Professor
Chen (33,35). SMX-NHOH (>99% by HPLC) was
synthesized according to Rieder et al (10). Dimethyl
sulfoxide (DMSO), Hybri-MaxTM, Triton® X-100,
L-lactic acid, iodonitrotetrazolium chloride (INT),
phenazine methosulfate (PMS), dithiothreitol (DTT),
iodoacetamide (IACD) and β-nicotinamide adenine
dinucleotide (NAD) were purchased from SigmaAldrich (Oakville, ON, Canada). All other chemicals
were purchased from BDH (Toronto, ON, Canada),
EMD (San Diego, CA, USA) or Sigma-Aldrich and
are the highest purity available commercially. Lipid
Hydroperoxide (LPO) Assay kits (96 well) and
Protein Carbonyl Assay kits were purchased from
Cayman Chemical Company (Ann Arbor, MI).
BD FalconTM 75 or 150 cm2 tissue culture flasks;
BD FalconTM 5 ml polypropylene round-bottom
tubes; BD FalconTM 5ml polystyrene round-bottom
test tubes; Falcon® Blue MaxTM 50 ml
polypropylene conical tubes; Falcon® MicrotestTM
tissue culture flat-bottom 96-well plates; and
Falcon® MultiwellTM tissue culture flat-bottom 12
well plates used for culture of cells were purchased
from BD Biosciences (Mississauga, ON).

Cytotoxicity Determined by Release of Lactate
Dehydrogenase (LDH) Activity
Cytotoxicity was determined by measuring the
release of LDH activity from cells into cell free
supernatant using a colorimetric assay previously
described (38). Briefly, Jurkat E6.1 cells were seeded
at 2×105 cells/ml for 6 h or 3×105 cells/ml for 24 h
experiments and treated with BE, Cro, Res, Sal, MIX
1 or MIX 2 (as described above) or 1% Triton X-100
(100% LDH release), the positive control. Cell
supernatant (100 μl) was incubated with 100 μl of
LDH Reaction Mixture (LDH Assay Kit) and
absorbance determined at 490 nm (Safire F129013,
Tecan, Austria); absorbance values were collected
using the XFluor 4 program. LDH leakage is
expressed as a percentage of the high control after all
values were adjusted using low control (solvent
treatment only).

Cell Culture and Treatment
The Jurkat E6.1 cells used throughout are a clone of
the Jurkat–FHCRC line, derived from the original
Jurkat cell line (36), and were obtained from the
ATCC (#TIB-152; http://www.atcc.org). RPMI
medium was prepared and adjusted to pH 7.2 by the
addition of 2 g sodium bicarbonate/L. Cell
concentrations were maintained between 1×105 and
1×106 cells/ml by replacing medium every 2 to 3
days. Before experiments, cells at room temperature
were transferred to 50 mL Falcon Blue tubes and
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concentration
of
2,4-dinitrophenylhydrazones
(yellow) in sample incubation mixtures formed by
reaction of protein aldehydes and ketones with 2,4dinitrophenylhydrazine (DNPH) to identical control
mixtures not reacted with DNPH. The amount of 2,4dinitrophenylhydrazones formed is quantified by
absorbance at 360 nm.
Cell preparation and treatment were as described
for the assay of lipid hydroperoxides (above). After
centrifugation, cells were resuspended and incubated
for 18 h at 37 ºC and 2 x 100 µl aliquots transferred
to 1.7 ml microcentrifuge tubes, one as sample, one
as control. DNPH reagent (400 µl) was added to the
sample tube, 2.5 M HCl (400 µl) to the control tube.
Tubes were incubated in the dark for 1 h with vortex
mixing every 15 min. Trichloroacetic acid (TCA; 0.5
ml 20%) was added to each tube to precipitate
protein which was collected following centrifugation
at 10,000×g for 10 min at 4 ºC. The protein pellet
was resuspended in 0.5 ml 10% TCA and samples recentrifuged at 10,000×g for 10 min at 4 ºC. The
supernatant was removed, the pellet resuspended in
0.5 ml ethanol: ethyl acetate (1:1) and the samples
centrifuged as before. The wash step with ethanol:
ethyl acetate was repeated twice and the final protein
pellet resuspended in 500 µl guanidine
hydrochloride solution by vortex mixing. Finally,
220 µl of the supernatant from sample tubes and 200
µl from control tubes were transferred to a 96-well
plate and the absorbance measured at 360 nm (Safire
F129013, Tecan, Austria). The concentration of 2,4dinitrophenylhydrazones is determined after
subtracting blank absorbance from sample
absorbance and converted to concentration using an
extinction coefficient of 22,000 M-1 (42).

Lipid Peroxidation
Lipid peroxide (LPO) formation was measured in
Jurkat E6.1 cells with a Lipid Hydroperoxide Assay
Kit that determines hydroperoxides directly (39),
subsequent to treatment with 400 µM SMX-NHOH
for 2 h with or without pretreatment for 30 min as
described above. Prior to treatment, Jurkat E6.1 cells
were washed with PBS, resuspended in RPMI 1640
medium with 0.2% v/v BSA (assay medium), and
adjusted to 5×105 cells/ml. Following incubation,
cells were spun at 500×g for 10 min, resuspended in
1ml RPMI1640 medium and incubated for 18 h at 37
ºC.
Treated cells were then transferred into glass test
tubes and sonicated in 500 µl HPLC-grade water. An
equal volume of Extract R saturated methanol
solution was added to each tube, followed by 1 ml
cold deoxygenated chloroform and thorough mixing.
Tubes were centrifuged at 500×g for 5 min at 4ºC,
the bottom chloroform layer collected and
transferred into another glass test tube, which was
stored at -80 ºC. An aliquot of the chloroform extract
(500 µl) was transferred to a glass tube, followed by
450 µl chloroform-methanol (2:1). Freshly prepared
chromogen (50 µl), consisting of equal volumes of
FTS Reagent 1 (4.5 mM ferrous sulphate in 0.2 M
HCl) and FTS reagent 2 (3% ammonium thiocyanate
in aqueous methanol) was added to each assay and
standard
tube
(50
µM
13-hydroperoxyoctadecadienoic acid (13-HpODE) in ethanol) and
the tubes sealed tightly for 5 min at room
temperature. Finally, 300 µl from each tube was
transferred to a 96-well glass plate and the
absorbance read at 500 nm (Safire F129013, Tecan,
Austria). Concentrations of lipid hydroperoxides
were calculated by comparison to the 13-HpODE
standard curve.

Reductive Two-Dimensional SDS-Polyacrylamide Gel Electrophoresis (R2D SDS-PAGE)
Prior to treatment, Jurkat E6.1 cells were washed in
PBS, resuspended in RPMI 1640 medium and the
density adjusted to 8×105 cells/ml. Cells were seeded
(2 ml/well) in 6-well tissue culture plates to yield
sufficient protein for analysis by R2D SDS-PAGE.
Jurkat E6.1 cells were pretreated as described in
detail above for 30 min, followed by treatment with
0 or 400 µM SMX-NHOH for 2 h.
After the 2.5 h incubation, cells were collected
in 2 ml microcentrifuge tubes at 500×g for 5 min.
Cell pellets were resuspended in PBS, centrifuged
again, resuspended in cold PBS and treated with 40
mM iodoacetamide (IACD) for 5 min to prevent
thiol-disulfide exchange and post-lysis oxidation of

Protein Carbonylation
Irreversible oxidation of Lys, Arg, Pro or Thr
residues in proteins to aldehydes and ketones is a
major pathway for protein modification during
oxidative stress, frequently resulting in loss of
function (40,41). Protein carbonyl content was
analyzed in experiments designed to study the
attenuation of SMX-NHOH-mediated protein
carbonylation in Jurkat E6.1 cells by pretreatment
with 5 or 20 µM BE, Cro, Res or Sal, and MIX 1 or
MIX 2 prior to exposure to 400 µM SMX-NHOH (as
described in more detail above).
We utilized the Caymen Chemical Protein
Carbonyl Assay kit (10005020) which compares the
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free cysteine thiols (43). After IACD incubation,
samples were recentrifuged and pellets resuspended
in 50 µl lysis buffer (one Roche Diagnostics protease
inhibitor tablet added to 9 ml lysis buffer, composed
of 7.44 mg EDTA, 0.12 g Tris, 0.76 g NaCl, 0.159 g
NaH2PO4·1H2O, 0.446 g Na4P2O7·10H2O, 0.042 g
NaF) dissolved in 100 µl water and frozen in liquid
nitrogen. The lysates were thawed at room
temperature, centrifuged for 10 min at 14,000×g, and
the mitochondrial supernatants collected. An aliquot
was assayed for protein content by the Bradford
procedure (44).
The gels for analysis in the first dimension (10%
acrylamide, 1.0 mm thickness) were prepared as
previously described (43). Protein extract (less than
50 µl) containing equal volumes of SDS sample
buffer and 85 µg of supernatant protein were
subjected to 10% non-reducing SDS-PAGE
electrophoresis for 3 h, using a constant current of 24
mA/gel with a Bio-Rad Protean II apparatus.
Different gel lanes contained proteins for each
individual treatment. After electrophoresis in the
first-dimension, each gel lane was cut, placed in an
individual glass dish and reduced with 10 ml SDS
sample buffer containing 100 mM DTT. Following 3
washes with SDS running buffer (1 min/time), each
gel lane was incubated in 10 ml SDS sample buffer
containing 100 mM IACD. Each gel lane was placed
horizontally on top of the second-dimension gel
(10% acrylamide, 1.5 mm thickness), fixed and
sealed with 2% low melt agarose buffer.
Electrophoresis was then performed in the second
dimension for 14 h at a constant current of 10 mA/gel
(43).
After electrophoresis, gel slabs were placed in a
Dodeca small stainer (Bio-Rad) for silver staining
where the gel was first fixed using methanol: water,
1:1 for 30 min and washed twice (5 min/each) with
distilled water to remove methanol. After that, gels
were incubated in sensitizer solution (0.02% sodium
thiosulfate) for 5 min, washed twice with distilled
water for 1 min each, immersed in cold 0.2% silver
nitrate solution and incubated for 30 min. Finally, gel
slabs were rinsed with distilled water twice for 1 min
and developed in an aqueous solution of 0.05%
formaldehyde in 3% sodium hydroxide. After the
developer solution turned yellow and the desired
intensity of staining (diagonal line and scattered
spots on the gel) was achieved, gel slabs were placed
in 5% acetic acid (45). Finally each gel slab was
scanned prior to analysis of resolved proteins.

STATISTICAL ANALYSIS
Analysis of variance (ANOVA) followed by
Bonferroni’s multiple comparison post-test was used
to test for statistical differences between groups. A
probability of more than 95% (P<0.05) was
considered to be significant. The Student’s t-test was
used in some cases to compare the vehicle control
and a treatment group; or to compare a TCM
treatment with the effect of SMX-NHOH alone.
GraphPad Prism Version 5.01 (GraphPad Software,
Inc) was used for statistical analyses.
RESULTS
Concentration-Dependent Cytotoxicity of TCM
Constituents and Defined Mixtures in Jurkat
E6.1 Cells
We initially assessed the cytotoxicity of BE, Cro,
Res, Sal, MIX 1 and MIX 2 in Jurkat E6.1 cells after
6 h incubation at concentrations ranging from 6.25 to
400 µM (Table 1). At 25 µM there was a small but
significant release of LDH upon exposure to BE
(1.6%) or Cro (1.9%) but no detectable cytotoxicity
with the other regimens. At 50 µM, LDH release
increased to approximately 3% with these two
compounds, still a low grade of toxicity. At the
exaggerated concentration of 400 µM (20-fold
greater than the highest chemoprotectant
concentration tested) Sal was the most cytotoxic of
the TCM constituents, releasing 27% of LDH while
Cro and MIX 1 (which contains Sal and Cro) each
released about 50% of this amount. Importantly, at
100 and 400 µM, MIX 2 was significantly less toxic
than all other TCM treatments, except for Sal at 100
µM and BE at 400 µM. In both these cases the mean
for LDH release was lower for MIX 1 than for Sal or
BE but the difference was not significant. We also
evaluated cytotoxicity after 24 h of exposure to each
of these regimens (data not shown). Not surprisingly
more LDH was released after 24 h than 6 h of
exposure (27.4±0.8 vs 6.9±0.3% for BE; 11.4±0.1 vs
3.3±9.1% for MIX 1. In addition, Sal was almost
twice as cytotoxic after 24 h than MIX 1, which
contained Sal (35.6±0.03 vs 19.5±0.2%). These latter
observations support our hypothesis that mixtures of
TCM agents will be less toxic than single chemicals
in complementary therapy.
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Table 1: Cytotoxicity of TCM phytochemicals studied for chemoprevention of SMX-NHOH toxicity assessed by % of
total LDH released from Jurkat E6.1 cells after incubation for 6 h. Data are expressed as mean ± SEM, N=3 separate cell
cultures.
TCM
6.25 µM
25 µM
50 µM
100 µM
400 µM
Baicalein
1.1±0.051
1.6±0.11
3.1±0.061,2
3.9±0.11,2
6.9±0.32
Crocetin
1.2±0.031
1.9±0.091,2
3.0±0.11,2
4.6±0.11,2
13.8±0.21,2
1,2
1,2
3.4±0.1
8.9±0.051,2
Resveratrol
0
0.7±0.08
1.1±0.05
2
Schisanhenol
0
0
0.2±0.1
2.8±0.2
26.8±0.31,2
MIX 13
0.03±0.007
0.6±0.1
2.3±0.11
3.6±0.11,2
12.8±0.21,2
MIX 24
0
0
0.04±0.002
0.4±0.03
3.3±0.12
1
P<0.05, within concentration comparison to MIX 2, the least cytotoxic of the TCM regimens at the highest concentration
(400 µM) tested
2
P<0.05, individual treatment vs 0 µM solvent control
3
MIX 1 is equimolar BE, Cro, Res and Sal
4
MIX 2 is equimolar BE, Cro and Res

significantly decreased the cytotoxicity of SMX-HA
in Jurkat E6.1 cells at 5 µM (Figure 3, Table 1). The
rank order (best to worst) of efficacy at 1 µM for
attenuation of SMX-NHOH toxicity is Cro, MIX 1,
MIX 2, Res, Sal and BE; and at 5 µM is MIX 1, MIX
2, Cro, Sal, Res and BE. BE offers significantly less
chemoprotection against SMX-NHOH cytotoxicity
than any of the other treatments (P<0.05; Table 2),
and although differences amongst the more
efficacious treatments are not significant, MIX 1 and
MIX 2 do comparatively well with over 90%
chemoprotection at 5 µM in each case.

Attenuation of SMX-HA-Mediated Cytotoxicity
in Jurkat E6.1 Cells by Pretreatment with TCM
Constituents Alone and in Defined Mixtures
The cytotoxicity of SMX-NHOH (400 µM treatment
for 2 h) was assessed by release of LDH from Jurkat
E6.1 cells in culture. Typically 28-32% of total
intracellular LDH was released when corrected for
release by solvent controls (Figure 3; 29.0 ± 4.7%,
mean ± SEM, N=3), a significant cytotoxic response
(P < 0.05 vs solvent controls). The observed
cytotoxicity is due both to the SMX-NHOH added to
the incubation mixture and to SMX-NO formed by
auto-oxidation during aerobic incubation (Figure 1).
Both of these metabolites are electrophiles,
accounting for the covalent binding of SMXNHOH/SMX-NO to cellular proteins (6,12,15,17).
They also contribute to cytotoxicity by depletion of
intracellular GSH, with increased lipid peroxidation
and irreversible oxidation of proteins occurring as
secondary effects.
To test for chemoprotection of the TCM
regimens against SMX-NHOH cytotoxicity we
pretreated Jurkat E6.1 cells with 1 or 5 µM of each
TCM (or 0.2% DMSO as solvent control) for 30 min
prior to exposure to the SMX metabolite. Each of
these treatments partially decreased the release of
LDH in a concentration-dependent manner. At 1
µM, Cro reduced LDH release by approximately
65% (vs solvent controls), a notable chemoprotective
effect. In comparison, MIX 1 decreased SMXNHOH-mediated release of LDH by 55% at 1 µM
and 93% at 5 µM (Table 2). In other words, pretreatment with 5 µM MIX 1 almost completely
attenuated the cytotoxicity of 400 µM SMX-NHOH
or SMX-HA (SMX-hydroxylamine) to E6.1 cells.
With the exception of BE, each of the TCM
ingredients and the 2 defined mixtures evaluated

Attenuation of SMX-NHOH-Mediated Lipid
Peroxidation in Jurkat E6.1 Cells by Pretreatment with TCM Constituents Alone and in
Defined Mixtures
Lipids are important structural components of cell
membranes and serve as primary targets for
oxidative modification by ROS radicals which
preferentially react with unsaturated fatty acids and
esters in membranes (46). In this context, lipid
peroxidation changes the structure and function of
membrane lipids and results in the formation of
highly reactive and unstable hydroperoxides. As
SMX-NHOH is known to cause oxidative stress
(13,14; Figure 1), its effects on lipid peroxidation
were evaluated under the same treatment conditions
(exposure to 400 µM SMX-NHOH for 2 h) used to
determine its cytotoxicity (Figure 3; Table 1). Upon
incubation with Jurkat E6.1 cells, SMX-NHOH
increased lipid peroxidation a bit more than 2-fold
(from 7.9 ± 0.5 to 16.8 ± 1.2 µmol lipid
hydroperoxides formed per incubation mixture)
compared to solvent controls (mean ± SEM, N=3;
Figure 4).
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Figure 3: Attenuation of LDH release from Jurkat E6.1 cells treated with SMX-NHOH (400 µM for 2 h) by pre-treatment
with 1 or 5 µM BE, Cro, Res, Sal, MIX 1 or MIX 2 for 30 min. Data are expressed as mean ±SEM, N= 3 different cell
cultures. MIX 1 is equimolar BE, Cro, Res and Sal; MIX 2 is equimolar BE, Cro and Res. *Significantly lower than SMXNHOH (400 µM) cytotoxicity (P<0.05; Student’s t-test (P<0.05) demonstrating attenuation of cytotoxicity by all treatments
except BE at 5 µM and only MIX 1 at 1 µM.
Table 2: Attenuation of the release of intracellular LDH from Jurkat E6.1 cells by pre-treatment with TCM constituents
alone or in defined mixtures for 30 min prior to treatment with 400 µM SMXNHOH for 2 h. Data are expressed as mean ±
SEM, N=3 different cell cultures.
TCM Treatment Regimen
% Decrease of LDH Release
Concentration
1 µM
5 µM
MIX 1
54.9 ±1.4
93.4 ±0.8
MIX 2
52.9 ±0.7
93.1 ±0.4
Crocetin
64.9 ±1.9
85.4 ±0.7
Resveratrol
39.9 ±0.9
79.8 ±0.7
Schisanhenol
39.5 ±2.6
82.4 ±1.3
Baicalein
30.9 ±1.21
57.5 ±1.91
1
Differences between % LDH released determined by Student’s t-test within each TCM concentration range (P<0.05, vs
MIX 1). TCM regimens are listed in decreasing order of efficacy at 1 µM. MIX 1 is equimolar BE, Cro, Res and Sal; MIX
2 is equimolar BE, Cro and Res.

attenuation of this lipid peroxidation is Cro, Res, Sal,
MIX 1, BE, and MIX 2; and at 20 µM is MIX 1, MIX
2, Res, Sal, Cro and BE. Chemoprotection against
lipid peroxidation was significantly greater at 5 µM
for Cro and Res than for BE (P<0.05; Table 2). All
TCM treatments were effective at 20 µM and
attenuated more than 80% of SMX-NHOHassociated lipid peroxidation. At 20 µM, MIX 1 and
MIX 2 each inhibited lipid peroxidation by more
than 93%.

To evaluate the ability of the 6 TCM treatments to
attenuate lipid peroxidation caused by 400 µM
SMX-NHOH, Jurkat E6.1 cells were pre-treated with
5 and 20 µM BE, Cro, Res, Sal, MIX 1 or MIX 2 for
30 min. These concentrations of TCM were not
cytotoxic because they did not increase LDH release
(Figure 3). At 5 or 20 µM each of the treatments with
single TCM chemicals and defined mixtures
significantly decreased lipid peroxidation (P<0.05)
caused by treatment with SMX-NHOH (Table 3).
The rank order (best to worst) of efficacy at 5 µM for
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Figure 4: Attenuation of lipid peroxidation in Jurkat E6.1 cells treated with SMX-NHOH (400 µM for 2 h) by pre-treatment
with 5 or 20 µM BE, Cro, Res, Sal, MIX 1 or MIX 2 for 30 min. Data are expressed as mean ± SEM, N= 3 different cell
cultures. Lipid peroxidation following each treatment was compared to that formed in SMX-NHOH-treated cells. MIX 1 is
equimolar BE, Cro, Res and Sal; MIX 2 is equimolar BE, Cro and Res. *Significantly lower than SMX-NHOH (400 µM)mediated lipid peroxidation (P<0.05; Student’s t-test) demonstrating significant attenuation of ROS toxicity by all TCM
treatments at 20 µM and at 5 µM.

cells were treated with 5 or 20 µM of pure TCM
constituents or the 2 defined mixtures for 30 min
before SMX-NHOH exposure (400 µM for 2 h). The
concentration of the phytochemicals used is the same
as for the lipid peroxidation experiments (Figure 4;
Table 3). Of the TCMs tested only Res significantly
increased protein carbonylation (vs solvent controls),
an effect that occurred at 5 µM but not 20 µM (data
not shown). An apparent but insignificant increase is
observed with 5 µM Sal (Figure 7).
Sal (5 µM and 20 µM) decreased protein
carbonylation due to SMX-NHOH by 45.8 ± 5.3%
and 71.3 ± 1.0 %, respectively (Figure 7; Table 4).
On the other hand, MIX 1 seemed slightly more
effective, inhibiting protein carbonylation by 74.5 ±
3.8% at 5 µM and 81.8 ± 3.9 % at 20 µM (Figure 8;
Table 2).
All TCM treatments were effective at 5 µM
because they inhibited SMX-NHOH-mediated
protein carbonylation by more than 45% (Table 3).
Protein carbonylation was inhibited more than 59%
by each TCM treatment regimen at 20 µM. There
seems an experimental anomaly here however,
because MIX 2 inhibited lipid peroxidation by

Attenuation of SMX-NHOH-Mediated Protein
Carbonylation in Jurkat E6.1 Cells by
Pretreatment with TCM Constituents Alone and
in Defined Mixtures
Irreversible protein oxidation is an important
toxication reaction in ROS and RNS pathology
(18,39.40), the reason we determined the effect of
SMX-NHOH exposure (400 µM for 2 h) on protein
carbonylation. To our knowledge this is the first time
this toxicological endpoint has been evaluated for
SMX-NHOH/SMX-NO in vitro. Incubation of
Jurkat E6.1 cells with SMX-NHOH increased
protein carbonyl formation by more than 2-fold
(245± 28%, mean ± SEM, N=3) for treated vs 100%
for solvent controls (Figure 7). Once again this
toxicological effect is almost certainly due to the
combined oxidative stressor and electrophilic
metabolite characteristics of SMX-NHOH and its
auto-oxidation product, SMX-NO because these two
electrophiles will deplete GSH before preferentially
binding to protein, enhancing ROS/RNS initiated
protein carbonylation.
To evaluate chemoprevention against SMXNHOH-mediated protein carbonylation, Jurkat E6.1

537

J Pharm Pharm Sci (www.cspsCanada.org) 18(4) 528 - 546, 2015

(41,43,47,48,49). Following depletion of GSH,
proteins are oxidized by ROS and RNS to proteinprotein disulfides which can be homodimeric (P-SSP) or heterodimeric (P-SS-P’). These disulfides are
the products detected by R2D SDS-PAGE, because
prior to PAGE in the second dimension, they are
reduced to monomeric protein thiols by 100 mM
DTT. Proteins with intramolecular double bonds are
also detected by this procedure because, upon
reduction, they show an apparent increase in
molecular weight (running to the left of the line of
identity in the redox 2D gel) as opposed to P-SS-P
and P-SS-P’ which show a dramatic decrease in mol
wt and run to the right of the line of identity (43). In
the presence of excess ROS and RNS almost all
proteins with reactive cysteine thiols become
irreversibly oxidized to their sulfinic acid (P-SO2H)
and sulfonic acid (P-SO3H) forms, a toxic response.
P-SO2H and P-SO3H are not detected by R2D SDS
PAGE because they are not reduced by 100 mM
DTT.
Spot 1 on the various gels is peroxiredoxin 2 (prx
2), a cytosolic protein we have identified as a major
disulfide in HEK 293 cells (human origin) by mass
spectrometry/peptide mass fingerprinting (MS/PMF)
after separation by R2D SDS-PAGE (50). Prx 2 is
clearly visible after R2D SDS-PAGE of
mitochondrial supernatant from untreated (data not
shown) or DMSO-treated Jurkat E6.1 cells (Figure
6A; solvent control). In addition to prx 2, four other
spots formed by reduction of P-SS-P/P’ are clearly
visible (labelled 2-5) in these DMSO-treated cells.
There are also 2 significant spots (6 and 7) that
appear to the left of the line of identity and are
proteins resulting from reduction of their
intramolecular disulfide bond(s) (43).

almost 70% at 5 µM but only 59% at 20 µM. The
rank order (best to worst) of efficacy at 5 µM for
chemoprevention of SMX-NHOH-mediated protein
carbonylation is MIX 1, MIX 2, Cro, Sal and BE. Res
showed negligible protection (6.1% inhibition). The
rank order at 20 µM is MIX 1, BE, Cro, Sal, Res and
MIX 2. At 5 µM, MIX 1 was significantly more
effective than Sal, BE and Res (Table 4). It was 20%
more effective than the other single constituent, Cro,
demonstrating the superiority of MIX 1 vs equimolar
concentrations of all single TCM phytochemicals
tested for suppression of protein carbonylation
(Table 3).
Attenuation of SMX-NHOH-Mediated Oxidative
Changes in the Disulfide Proteome in Jurkat E6.1
Cells by Pretreatment with TCM Constituents
Alone and in Defined Mixtures
The disulfide proteome is comprised of a small subsection of proteins, numbering in the hundreds, that
are redox-regulated by oxidation of a reactive
cysteine thiol moiety (41,42,43,47-49). Reactive
cysteine thiols are ionized at physiological pH
making them more nucleophilic and more easily
oxidized by ROS and RNS. After initial oxidation
with H2O2 protein reactive cysteine thiols are
converted to their sulfenic acid (P-SOH) derivatives
which react rapidly with GSH to yield Sglutathionylated products, called glutathione-protein
mixed disulfides (P-SS-G). Protein reactive cysteine
thiols also react with NO, possibly via NO-GSH to
form S-glutathionylated proteins (41,48,49). SGlutathionylated proteins and protein-protein
disulfides are readily converted back to thiols as the
cell becomes more reduced, the reason Sglutathionylation is cytoprotective for exposure to
moderate concentrations of ROS and RNS

Table 3: Attenuation of lipid peroxidation in Jurkat E6.1 cells by pre-treatment with TCM constituents alone or in
defined mixtures for 30 min prior to treatment with 400 µM SMX-NHOH for 2 h. Data are expressed as mean ± SEM,
N=3 separate cell preparations. MIX 1 is equimolar BE, Cro, Res and Sal; MIX 2 is equimolar BE, Cro and Res.
TCM Treatment Regimen
% Decrease of Lipid Hydroperoxide Formation
Concentration
5 µM
20 µM
Resveratrol
71.8 ±3.71
92.5 ±3.1
83.8 ±1.6
Crocetin
72.1 ±1.71
Schisanhenol
65.8 ±4.7
91.1 ±3.4
MIX 1
47.0 ±1.0
95.6 ±5.1
Baicalein
44.2 ±3.6
81.5 ±2.1
MIX 2
41.6 ±1.1
93.4 ±5.9
1
Differences between lipid peroxide formed by exposure to SMX-NHOH determined by Student’s t-test within each
concentration range (P<0.05 vs MIX 1). TCM regimens are listed in decreasing order of efficacy at 5 µM.
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Figure 5. Attenuation of protein carbonylation in Jurkat E6.1 cells treated with SMX-NHOH (400 µM for 2 h) by pretreatment with 5 or 20 µM BE, Cro, Res, Sal, MIX 1 or MIX 2 for 30 min. Data are expressed as mean ± standard error, N=
3 different cell cultures. MIX 1 is equimolar BE, Cro, Res and Sal; MIX 2 is equimolar BE, Cro and Res.*Significantly lower
than SMX-NHOH (400 µM)-mediated protein carbonylation (P<0.05; Student’s t-test) demonstrating significant attenuation
of irreversible protein oxidation at carbonyl by Cro and MIX 1 at 5 and 20 µM and MIX 2 only at 5 µM.

Table 4. Attenuation of SMX-NHOH initiated protein carbonylation in Jurkat E6.1 cells by pre-treatment with 5 or 20
µM BE, Cro, Res, Sal, MIX 1 or MIX 2 for 30 min. Data are expressed as mean ± SEM, N= 3 different cell cultures. The
decrease in protein carbonylation for each of the other treatments was compared to chemoprotection of MIX 1 (Student’s
t-test; 1P<0.05 vs MIX 1).
Effect of pre-treatment with TCM on protein carbonylation due to treatment with SMXNHOH (400 µM; 2h) (% decrease; mean ± SEM, N=3)
Compound
5 µM
20 µM
MIX 1
74.5 ±3.8
81.8 ±3.9
MIX 2
66.8 ±5.2
59.2 ±6.5
Crocetin
55.0 ±4.3
71.8 ±1.9
Schisanhenol
45.8 ±5.31
71.3 ±1.9
73.6 ±1.8
Baicalein
45.7 ±5.51
Resveratrol
6.1 ±1.41
62.6 ±8.6

Jurkat E6.1 cells also contained several novel spots,
labelled by the letters “a” through “l” in Figure 6B
and Table 5.
Jurkat E6.1 cells also contained several novel
spots, labelled by the letters “a” through “l” in Figure
6B and Table 5. Most of these SMX-NHOH-specific
protein spots from DDT reduction of intermolecular
protein disulfides (i.e. spots were below and to the
right of the line of identity). These novel disulfides
were formed by oxidation of proteins at reactive
cysteine thiols by SMX-NHOH.

Upon treatment with 400 µM SMX-NHOH there
are significant oxidative changes to the disulfide
proteome of Jurkat E6.1 cells. The most dramatic is
the disappearance of prx 2, which occurs in untreated
cells as a disulfide-linked dimeric protein, prx2-SSprx2 which is reduced to prx2-SH by DTT. Prx2 is a
2-Cys peroxiredoxin involved in the reduction of
low, endogenous concentrations of H2O2 (51-54).
Prx2 is oxidized to prx2-SO2H by SMX-NHOH
(Figure 6B) and other oxidative stressors including tbutyl hydroperoxide (50). SMX-NHOH-treated
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Figure 6. Continued…..

1
1

Figure 6. Chemoprotective effects of 5 µM BE (C), Cro (D), Res (E), Sal (F), MIX 1 (G) or MIX 2 (H) on 400 µM SMXNHOH-induced oxidation of Jurkat E6.1 cells (B) analyzed by R2D SDS PAGE and silver staining. The protein spots seen
in the vehicle control (A) are identified by numbers (1-7) whereas those that occur only after treatment with SMX-NHOH
are identified by letters (a-l; Table 5). Mitochondrial supernatant (85 µg protein) was loaded on all gels which were run in
triplicate for each experiment, and the experiment was repeated three times with different cell cultures (i.e. 9 gels for each
treatment).

MIX 2 (Figure 6H) than with any of the single
treatments.
Each of the numbers in Table 5 represents the
number of experiments in which a specific spot was
found. Thus, 1 µM BE, Res and Sal did not attenuate
the disappearance (hyperoxidation) of prx2 whereas
each of the other treatments did. One way to assess
the chemoprotection of the various TCM regimens
against SMX-NHOH-dependent oxidation of the
disulfide proteome is to compare the number of spots
that disappear (i.e. protein-protein disulfides that are
no longer formed). At 5 µM. this number is 5 for
BE; 6 for Cro; 6 for Res; 7 for Sal; 7 for MIX 1; and
7 for MIX 2, demonstrating that all regimens were
able to partially protect against P-SS-P/P’ formation.
When both endpoints are considered, it is clear that
the chemoprotection offered by MIX 1 and MIX2
against oxidation of redox-regulated proteins by
SMX-NHOH is better than for any of the single TCM
constituents.

The effectiveness of the inhibition of oxidation
of the disulfide proteome by the various TCM
treatments was evaluated using 2 criteria; first by
examining the presence and relative size of prx 2
(spot 1) in the gels; and second, by determining
changes in SMX-NHOH-specific spots (Table 5).
Based on an analysis of prx 2 hyperoxidation
(disappearance), each of the single TCM compounds
and defined mixture treatments partially attenuated
oxidation of the disulfide proteome. The prx 2 spot
which is prominent in solvent controls (Figure 6A) is
absent from mitochondrial supernatant of Jurkat
E6.1 cells treated with 400 µM SMX-NHOH for 2 h
(Figure 6B). A faint prx 2 spot, indicating partial
chemoprotection from SMX-NHOH is visible in gels
from cells pretreated with 5 µM BE (Figure 6C), Cro
(Figure 6D), Res (Figure 6E), Sal (Figure 6F), MIX
1 (Figure 6G) or MIX 2 (Figure 6H) before SMXNHOH. It is clear from Figure 6 that more prx 2 is
present in cells pretreated with MIX 1 (Figure 6G) or
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Table 5. Protein spots on R2D SDS-PAGE gels formed by reduction of protein-protein disulfides (a-l) or by preventing
oxidation of peroxiredoxin 2 (spot 1) to prx2 sulfinic acid. The numbers represent the number of experiments of a total of 3
where a specific spot was present on the gel.
25
30
35
37
39
60
65 90 112 114 115 116 130
Monomeric mol wt (kDa)1
Protein spots2
1
a
b
c
d
e
f
g
h
i
j
k
l
Control (0.2% DMSO)
3
0
0
0
0
0
0
0
0
0
0
0
0
SMX-NHOH (400 µM) [HA]
0
3
2
2
3
3
2
3
2
3
3
2
2
1 µM BE + HA
0
3
0
0
3
3
1
3
0
2
2
0
1
5 µM BE + HA
3
2
0
0
1
0
1
3
0
2
2
0
1
1 µM Cro + HA
3
1
0
0
0
3
3
3
3
0
1
2
0
5 µM Cro + HA
3
2
0
0
2
3
2
1
0
0
0
0
2
1 µM Res + HA
0
3
0
2
2
3
2
1
2
0
0
0
2
5 µM Res + HA
3
3
0
0
3
3
2
2
0
0
0
0
1
1 µM Sal + HA
0
3
0
1
0
2
3
3
2
3
0
0
0
5 µM Sal + HA
3
3
0
0
0
3
3
2
0
0
0
1
0
1 µM MIX 1 + HA
3
1
0
0
0
0
3
3
3
2
3
2
0
5 µM MIX 1 + HA
3
0
0
0
0
0
3
3
3
0
2
0
3
1 µM MIX 2 + HA
3
0
0
0
1
1
3
3
3
2
2
1
0
5 µM MIX 2 + HA
3
0
0
0
3
3
3
3
0
0
3
0
0
1
Mol wt in kDa estimated using mol wt markers on R2D SDS-PAGE slab gels
2
Spot 1 is prx 2; spots a-l appear only upon treatment of Jurkat E6.1 cells with 400 µM SMX-NHOH

47,48,50,56,57).
Depleted intracellular GSH
facilitates increased covalent binding of SMXNHOH and SMX-NO to proteins (increased hapten
formation) (Figure 1; 14,15) and increased oxidation
of redox-regulated proteins to irreversible products
such as P-SO2H, P-SO3H and polymeric protein
disulfides (40,42,46,47), known contributors to
pathology.
We hypothesize that complementary therapy
with either single or defined, simple mixtures of
TCM constituents with potent antioxidant activity
will attenuate SMX-mediated ADRs by: 1)
decreasing formation of ROS/RNS and/or increasing
detoxication of these radicals, enhancing
intracellular GSH (decrease GSSG/GSH ratio); and
2) increasing metabolic detoxication of SMXNHOH and SMX-NO by GSH-dependent pathways.
In this study we were able to show that mixtures are
less cytotoxic than single TCM constituents at
equimolar concentrations (Table 1).
Exposure of Jurkat E6.1 cells in culture to SMXNHOH (400 µM for 2 h) initiated several responses
associated with toxicity. This oxidative metabolite of
SMX caused significant (P<0.05) release of 28-32%
of total intracellular LDH, a sensitive assay for
cytotoxicity (Figure 3; Table 2); a more than 2-fold
increase in lipid peroxide content, an index of
oxidative/nitrosative stress (Figure 4, Table 3); a
significant
increase
(P<0.05)
in
protein
carbonylation, a biomarker for irreversible protein
oxidation by ROS/RNS, by 145% (250± 28%, mean
± SEM, N=3 vs 100%, in solvent controls) (Figure 5;

However, on the positive side, it is equally
obvious that all treatment regimens tested are
chemoprotective against SMX-NHOH-dependent
oxidation of proteins at ionized cysteine thiols, a
probable contributing mechanism to the ADRs to
SMX via immunogenic hapten formation.
DISCUSSION
It is now well established that ADRs to the
sulfonamide, SMX are caused by its electrophilic
metabolite, SMX-NHOH (formed by cytochrome
P450 monooxygenases in liver and extrahepatic
tissues; and MYO in blood cells) and its autooxidation product, SMX-NO. Both SMX-NHOH
and SMX-NO show selectivity when they bind
covalently to proteins to form haptens (Figure
1;2,6,12,15,17), indicating probable covalent
reaction with protein reactive cysteine thiols (54).
AIDS patients have depleted intracellular GSH (i.e.
increased GSSG/GSH ratio), contributing to the 50%
incidence of ADRs to SMX therapy in this group vs
3-4% in the normal population (2). This extremely
high ADR incidence in these oxidatively stressed
patients reflects the fact that SMX-NHOH and SMXNO are both electrophilic and oxidative stressors,
dual contributors to SMX hypersensitivity (Figure 1;
6,10,11,12,14). In addition, GSH is required for
detoxication both of the electrophilic SMX
metabolites, (by formation of GSH conjugates; 6,10)
and the ROS/RNS they indirectly generate (by
formation
of
S-glutathionylated
proteins;
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TCM treatment regimens offered chemoprotection
against SMX-NHOH-induced lipid peroxidation.
Both mixtures inhibited about 95% of lipid
peroxidation at the higher concentration (20 µM)
studied (Table 2). In addition, all TCM treatments
inhibit SMX-NHOH-mediated protein carbonylation
at 5 µM by more than 45% but MIX 1 attenuated
protein carbonylation by 20% more than any of the
single treatments (although this difference is not
significant, Table 3).
With regard to partially preventing the SMXNHOH-dependent hyperoxidation of prx 2 to its
sulfinic acid form, all treatments showed partial
chemoprotection at 5 µM but only Cro, MIX 1 and
MIX 2 did so at 1 µM in 3 independent experiments
(Figures 6C to 6H; Table 5). However, MIX 1 and
MIX 2 are slightly superior chemoprotectants
(Figures 6G and 6H; larger prx 2 spot) than
equimolar concentrations of BE, Cro, Res or Sal
(Figures 6C to 6F).
Another significant change that occurred in the
disulfide proteome as the result of exposing Jurkat
E6.1 cells to SMX-NHOH was the appearance of 12
specific monomeric protein thiol spots on R2D SDSPAGE gels never present in solvent controls (Figure
6B vs 6A; Table 4). The mol wt of the spots present
in all 3 experiments was determined from the R2D
SDS-PAGE gels (a, 30 kDa; d, 39 kDa; e, 60 kDa;
g, 90 kDa; i, 114 kDa and j, 115 kDa) and the other
6 (b, 35 kDa; c, 37 kDa; f, 65 kDa; h,112 kDa; k,116
kDa; and l, 130 kDa were present on gels from 2 of
the 3 experiments. Although these protein spots were
not identified in our study redox-regulated proteins
containing reactive cysteine thiol of identical mol wt
were previously identified in Jurkat cells (56) and in
T cell blasts (57) subjected to oxidative stress. Thus,
the protein at 114 kDa (i) is possibly ubiquitin
thiolesterase 16; at 60 kDa (e), HSP 60; at 39 kDa
(d), GAPDH or aldolase; and at 37 kDa (b), αenolase.
As a result of this proof-of-principle study we
believe that carefully designed mixtures of potent
phytochemicals with different mechanisms of
chemoprotective action have potential for
complementary therapy against ADRs where
oxidative and nitrosative stress play a causative role.
This potential can be increased by including
ingredients which are rapidly absorbed, initiate their
activity quickly and are rapidly eliminated as
conjugates formed directly by rapid phase 2
metabolism, in addition to compounds like Sal which
have prolonged bioactivity in vivo due to the

Table 4); and significant oxidation of redox proteins
regulated by reactive (ionized) cysteine thiol
residues (i.e. oxidative changes to the disulfide
proteome by ROS/RNS) as shown by 1) the
hyperoxidation of prx 2 (Figure 6, Table 5); and 2)
the appearance of 12 novel SMX-NHOH-specific
monomeric protein thiols, labelled “a” to “l”,
following DTT reduction of protein-protein
disulfides (Figure 6B; Table 5). There are probably
more redox-regulated proteins in Jurkat E6.1 cells
oxidized by SMX-NHOH not detected in our R2D
SDS-PAGE experiments. This is because a
limitation of this technique is that it only works well
for cellular proteins present at relatively high
concentrations.
A related mass spectroscopy (MS)-based
proteomic study of Jurkat cells treated with 200 µM
H2O2 for 10 min identified 28 spots that were
reversibly oxidized (i.e. P-SS-G, P-SS-P or P-SS-P’)
and 24 spots that decreased in intensity/size
following oxidation, including prx 2 (56). A second
MS-based study identified 38 different redoxregulated proteins in T cell blasts that form Sglutathionylated derivatives (P-SS-G) upon
oxidation with 1 mM H2O2 or 1 mM Diamide for 5
min (57).
This collection of toxicological endpoints
(cytotoxicity,
lipid
peroxidation,
protein
carbonylation and oxidation of the disulfide
proteome) for SMH-NHOH allowed us to evaluate
the chemoprotection provided against this SMX
metabolite by low concentrations of BE, Cro, Res or
Sal and 2 defined mixtures; MIX 1 which contains
equimolar amounts of all 4 phytochemicals and MIX
2, an equimolar mixture of BE, Cro and Res. One
reason for comparing these mixtures to each other
was to evaluate the contribution of poorly
investigated Sal to chemoprotection in the presence
of other well characterized antioxidants.
All chemicals evaluated effectively protect
against SMX-NHOH cytotoxicity at 1 µM (31-65%
attenuation of LDH leakage) or 5 µM (57-93%
attenuation; Table 1). The only significant difference
noted is that BE is less effective than MIX 1 at both
concentrations (P<0.05). The mean attenuation with
MIX 1 was 55% at 1 µM and 93% at 5 µM; that for
MIX 2 was 53% and 93%, respectively. These were
the only treatments that exceeded 90% efficacy at 5
µM. In terms of cytotoxicity, none of the treatments
cause any increase in LDH release, compared to the
solvent control at the concentrations tested for
chemoprotection (Table 1; Figure 3). Similarly, all
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conversion of 5 phenolic methyl ethers to antioxidant
phenols by slower phase 1 cytochrome P450dependent oxidation.
9.
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